Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system

Introduction. Presently, the willingness-to-pay threshold (cost-effectiveness threshold, incremental cost-effectiveness ratio) is used as one of the decision-making criteria for reimbursement in some foreign countries with a developed system of healthcare technologies evaluation (HTE). However, in R...

Full description

Bibliographic Details
Main Authors: T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky
Format: Article
Language:Russian
Published: IRBIS LLC 2021-02-01
Series:Фармакоэкономика
Subjects:
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/452
_version_ 1797878872929206272
author T. S. Teptsova
N. Z. Musina
V. V. Omelyanovsky
author_facet T. S. Teptsova
N. Z. Musina
V. V. Omelyanovsky
author_sort T. S. Teptsova
collection DOAJ
description Introduction. Presently, the willingness-to-pay threshold (cost-effectiveness threshold, incremental cost-effectiveness ratio) is used as one of the decision-making criteria for reimbursement in some foreign countries with a developed system of healthcare technologies evaluation (HTE). However, in Russia, the willingness-to-pay threshold (WPT) is undetermined, which complicates the evaluation of clinical-economical effectiveness of medical technologies, including medicines.Aim. The study aimed to calculate WPT for the Russian healthcare system using the available foreign experience.Materials and Methods. WPT was calculated with the following methods: the method proposed by the WHO, hemodialysis cost-effectiveness standard, case-based reasoning (CBR), and the evaluation of the shadow cost of the budget.Results. WPT was calculated for the Russian healthcare system using four different methods of calculation. According to the method proposed by the WHO, WPT was 2,235,201.60 Rub for DALY in the RF; according to the hemodialysis cost-effectiveness standard, it was 1,748,623.36 Rub for QALY; according to the method of the evaluation of the shadow cost of the budget, it was 313,878.21 Rub for DALY and 365,060.31 Rub for QALY; and according to the method of the case-based reasoning, it was 7,494,944.00 Rub for QALY.Conclusion. The study results showed that the optimal WPT values for the Russian healthcare system were those obtained by the method of the WHO (2,235,201.60 Rub). The authors propose to use this value as one of the decision-making criteria for the reimbursement of medical technologies, including medicinal drugs.
first_indexed 2024-04-10T02:39:56Z
format Article
id doaj.art-5134d26ead4649258bfe6bbe8ba84fe1
institution Directory Open Access Journal
issn 2070-4909
2070-4933
language Russian
last_indexed 2024-04-10T02:39:56Z
publishDate 2021-02-01
publisher IRBIS LLC
record_format Article
series Фармакоэкономика
spelling doaj.art-5134d26ead4649258bfe6bbe8ba84fe12023-03-13T07:48:17ZrusIRBIS LLCФармакоэкономика2070-49092070-49332021-02-0113436737610.17749/2070-4909/farmakoekonomika.2020.071321Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare systemT. S. Teptsova0N. Z. Musina1V. V. Omelyanovsky2Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian FederationCenter for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation; Saint Petersburg State Chemical Pharmaceutical University; Russian Presidential Academy of National Economy and Public Administration; Russian Medical Academy of Postgraduate EducationCenter for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation; Russian Medical Academy of Postgraduate Education; Financial Research Institute of the Ministry of Finance of the Russian FederationIntroduction. Presently, the willingness-to-pay threshold (cost-effectiveness threshold, incremental cost-effectiveness ratio) is used as one of the decision-making criteria for reimbursement in some foreign countries with a developed system of healthcare technologies evaluation (HTE). However, in Russia, the willingness-to-pay threshold (WPT) is undetermined, which complicates the evaluation of clinical-economical effectiveness of medical technologies, including medicines.Aim. The study aimed to calculate WPT for the Russian healthcare system using the available foreign experience.Materials and Methods. WPT was calculated with the following methods: the method proposed by the WHO, hemodialysis cost-effectiveness standard, case-based reasoning (CBR), and the evaluation of the shadow cost of the budget.Results. WPT was calculated for the Russian healthcare system using four different methods of calculation. According to the method proposed by the WHO, WPT was 2,235,201.60 Rub for DALY in the RF; according to the hemodialysis cost-effectiveness standard, it was 1,748,623.36 Rub for QALY; according to the method of the evaluation of the shadow cost of the budget, it was 313,878.21 Rub for DALY and 365,060.31 Rub for QALY; and according to the method of the case-based reasoning, it was 7,494,944.00 Rub for QALY.Conclusion. The study results showed that the optimal WPT values for the Russian healthcare system were those obtained by the method of the WHO (2,235,201.60 Rub). The authors propose to use this value as one of the decision-making criteria for the reimbursement of medical technologies, including medicinal drugs.https://www.pharmacoeconomics.ru/jour/article/view/452cost-effectiveness thresholdwillingness-to-pay thresholdincremental cost-effectiveness ratioreference value of the icerquality-adjusted life years qalylife years gainedlygdisability-adjusted life yeardaly
spellingShingle T. S. Teptsova
N. Z. Musina
V. V. Omelyanovsky
Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system
Фармакоэкономика
cost-effectiveness threshold
willingness-to-pay threshold
incremental cost-effectiveness ratio
reference value of the icer
quality-adjusted life years qaly
life years gained
lyg
disability-adjusted life year
daly
title Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system
title_full Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system
title_fullStr Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system
title_full_unstemmed Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system
title_short Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system
title_sort evaluation of the reference value of the incremental parameter cost effectiveness for russian healthcare system
topic cost-effectiveness threshold
willingness-to-pay threshold
incremental cost-effectiveness ratio
reference value of the icer
quality-adjusted life years qaly
life years gained
lyg
disability-adjusted life year
daly
url https://www.pharmacoeconomics.ru/jour/article/view/452
work_keys_str_mv AT tsteptsova evaluationofthereferencevalueoftheincrementalparametercosteffectivenessforrussianhealthcaresystem
AT nzmusina evaluationofthereferencevalueoftheincrementalparametercosteffectivenessforrussianhealthcaresystem
AT vvomelyanovsky evaluationofthereferencevalueoftheincrementalparametercosteffectivenessforrussianhealthcaresystem